MS Speaks

Some of the authors of the article abstracted here are well known in MS research. From PubMed (August 10, 2020)--"Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment":


https://pubmed.ncbi.nlm.nih.gov/32767538/


Note that clicking on the DOI in the abstract will take you to the entire article.


There is also this--also indexed in PubMed (August 10) and with some of the same authors--"Serious safety events in rituximab-treated multiple sclerosis and related disorders":


https://pubmed.ncbi.nlm.nih.gov/32767538/